Success Stories
Highlights of the PCI news focused on Penn commercialization accomplishments
ViTToria Biotherapeutics Secures $15M
ViTToria is focused on developing novel CAR-T cell therapies that transcend the limitations of current cell therapies.
Heirloom Opens First Commercial Carbon Capture Plant in the U.S.
Heirloom uses a process called direct air capture to remove greenhouse gases from the atmosphere.
Penn spinout Interius Biotherapeutics raises another $21.5M
Co-founded by Saar Gill, MD, PhD, Interius is developing a new platform for cell-specific gene delivery in patients.
PCI Recognized In Clinical Leader Article about How Academic Medical Centers Can Capture Greater Value In The Cell & Gene Therapy Industry
The Penn Center of Innovation was recognized in an article in Clinical Leader about how academic medical centers can leverage their unique advantages to develop and deliver cell and gene therapies.
Penn grads develop The Community Grocer to provide hot food for those using SNAP benefits
Penn graduates Alex Imbot ‘20 and Eli Moraru ‘21 were featured in the Inquirer for their non-profit corner store idea, The Community Grocer, which improves food access for those using SNAP benefits.
Penn is the one of the world’s best universities for VC-seeking entrepreneurs, per PitchBook data
PitchBook released its 2023 list of the best universities for founders, and Penn ranked fourth among undergraduate schools with 1,083 founders, 993 companies and $34 billion raised.
Press Highlights of FY23
During the 2022 fiscal year, there were 98 press mentions for PCI programs, startups and partners. Some of the most popular and widely circulated stories are included here.
Apellis Receives FDA Approval for SYFOVRE™ (pegcetacoplan injection) as the First Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
Penn spinout Apellis Pharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for their drug SYFOVRE™ (pegcetacoplan injection).
Verismo Therapeutics featured in the Philadelphia Business Journal for recent funding
The cell therapy startup recently raised $17 million to advance its lead immunotherapy candidates in a second pre-Series A round of funding.
Verismo Therapeutics raises funding and expands partnership with Penn Medicine
Penn spinout company Verismo Therapeutics has successfully raised $7 million in a pre-Series A round led by BRV Capital Management.